Ketan Desai, MD, PhD, is the Founder and Chief Executive Officer of IMC Radiology, the founder and Chief Medical Officer of LeVolta Pharma (biotechnology), Founder and Chairperson of Omega Skin Solutions ...more Ketan Desai, MD, PhD, is the Founder and Chief Executive Officer of IMC Radiology, the founder and Chief Medical Officer of LeVolta Pharma (biotechnology), Founder and Chairperson of Omega Skin Solutions (cosmetics and dermatology), One of his inventions was acquired by Nutent Therapeutics (nutraceuticals) and is on the market. Dr. Desai is a published author (Germs of War). He has 13 awarded patents sees patients one day a week for rheumatology and allergic diseases
less
Latest Comments
Review Of Present Therapies For Covid-19
CYDY is still a garbage company. Nothing has changed there. Dont know why the chart is no longer showing. Must be some software problem at TM
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
What is sad is your ignorant pumping. Nothing was done to this stock, it went down as there was no science, no management, no clinical or regulatory path forward. And no, it does not go to show any stock has "unknown things and is unpredictable" - I've been bearish on this for over a year while you were shamelessly pumping.
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
Still pumping this garbage? Has failed every study, been scoled by the FDA for lying, has had 25 different firms file lawsuits, lost a distributor in US, and stock is now down to $1.40 or thereabouts. When you started pumping this stock, it was in the $4 range. Have you no shame?
Review Of Present Therapies For Covid-19
Thanks. Your point of placebo is well taken. Often though, it is not true placebo. The design is standard of care plus study drug versus standard of care plus placebo. The patients thus get the minimum of standard of care.
Review Of Present Therapies For Covid-19
Thanks
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
Written by Cytodyn insiders!! What conflict of interest!! Zero credibilty!! LOL!!!!
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
What an ignorant and biased rant. Look at these reviews on the status of immune response to COVID19. These are by independent scientists who, unlike you or Cytodyn, have no conflict of interest. They are peer reviewed and are in world class journals Sciene, Lancet. CCR5 is not a pathway that anyone of repute espouses.
www.sciencedirect.com/.../S1074761320301837
science.sciencemag.org/content/369/6508/eabc8511
www.thelancet.com/.../fulltext#seccestitle60
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
What a poor response. You DID NOT SHOW A SINGLE PEER REVIEWED INDEPENDENT ARTICLE ON CCR5 AND COVID19. We are not talking about HIV but COVID19. Stay on topic, will you, and stop dissembling the truth?
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
www.frontiersin.org/.../full
CytoDyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
Scientific knowledge that Cytodyn pumpers dont know or deliberately obfuscate - neutrophils in COVID19 are determined by CCR8, and not CCR5. See article below. Leronlimab binds CCR5, not CCR8. Which is why other than Cytodyn, NOBODY IN THE SCIENTIFIC OR PHARMA COMMUNITY trusts cytodyn data.